EUVIMEDEUVIMED entdecken
Crossref

Dose‐escalated biologic therapy improves outcomes in people with inflammatory bowel disease

Wai Kin Su iD, William Wilson, Susan J Connor iD, Jane M Andrews iD

Internal Medicine Journal · 28.07.2026

DOI: 10.1111/imj.70562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 28.07.2026. Verfasst von Wai Kin Su und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Liverpool Hospital, Liverpool, New South Wales, Australia. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologic therapies are effective in inflammatory bowel disease (IBD), yet many people do not achieve adequate or sustained response to standard dosing, which necessitates dose escalation (DE).

Aim

To examine the need for DE and subsequent outcomes in a large real‐world cohort.

Methods

Crohn's colitis care (CCCare) is an electronic medical record used in Australasia. Data flow into a de‐identified clinical quality registry (CQR), which was interrogated in November 2024. DE was defined as maintenance dosing exceeding the standard average daily dose. We examined data before and over 12 months following DE.

Results

Of 6093 courses of biologic therapy, 37.3% ( n = 2272) were DE therapy. Most were for Crohn's disease ( n = 4208, 69.1%); median time from initiating therapy to DE was 5 months (IQR: 0–19), and 74.2% ( n = 1685) remained on DE therapy beyond 12 months. Twelve months post DE, significant increases in remission rates were seen as assessed by faecal calprotectin

Schlagwörter

Stichwörter der Autor:innen

biologic therapydose escalated therapyhealthcare utilisationinflammatory bowel diseaseremission

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Liverpool Hospital, Liverpool, New South Wales, Australia.
  • Crohn's Colitis Cure, Sydney, Australia.
  • Gastroenterology and Liver, The Ingham Institute for Applied Medical Research, Liverpool, Australia.
  • Department of Anaesthesia, Lyell McEwin Hospital, Adelaide, Australia.
  • Medicine and Health (South Western Sydney Clinical School), University of New South Wales, Sydney, Australia.
  • Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, Australia.

ORCID-Profile: Wai Kin Su, Susan J Connor, Jane M Andrews

Zitieren

APA

Su, W. K., Wilson, W., Connor, S. J., & Andrews, J. M. (2026). Dose‐escalated biologic therapy improves outcomes in people with inflammatory bowel disease. Internal Medicine Journal. https://doi.org/10.1111/imj.70562

Vancouver

Su WK, Wilson W, Connor SJ, Andrews JM. Dose‐escalated biologic therapy improves outcomes in people with inflammatory bowel disease. Internal Medicine Journal. 2026. doi:10.1111/imj.70562

BibTeX
@article{Su2026,
  author = {Su, Wai Kin and Wilson, William and Connor, Susan J and Andrews, Jane M},
  title = {Dose‐escalated biologic therapy improves outcomes in people with inflammatory bowel disease},
  journal = {Internal Medicine Journal},
  year = {2026},
  doi = {10.1111/imj.70562}
}
Kostenlos starten →